CymaBay Therapeutics Inc (NASDAQ:CBAY) – Analysts at Leerink Swann dropped their FY2019 earnings estimates for CymaBay Therapeutics in a report issued on Tuesday. Leerink Swann analyst J. Schwartz now expects that the biopharmaceutical company will earn ($1.13) per share for the year, down from their prior forecast of ($1.06). Leerink Swann has a “Buy” rating and a $16.00 price target on the stock.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.02). During the same period in the prior year, the company posted ($0.25) earnings per share.

A number of other equities research analysts have also recently weighed in on CBAY. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of CymaBay Therapeutics in a report on Tuesday. Cantor Fitzgerald reaffirmed a “buy” rating and set a $16.00 price target on shares of CymaBay Therapeutics in a report on Wednesday, November 8th. Oppenheimer set a $15.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a report on Monday, October 30th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $12.00 price target on shares of CymaBay Therapeutics in a report on Friday, October 27th. Finally, SunTrust Banks started coverage on CymaBay Therapeutics in a report on Friday, August 18th. They set a “buy” rating and a $15.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $14.50.

CymaBay Therapeutics (NASDAQ CBAY) opened at $8.71 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39. CymaBay Therapeutics has a 52-week low of $1.46 and a 52-week high of $9.40.

In related news, Director Kurt Von Emster sold 50,048 shares of CymaBay Therapeutics stock in a transaction on Friday, November 10th. The stock was sold at an average price of $9.26, for a total transaction of $463,444.48. Following the completion of the sale, the director now directly owns 90,000 shares of the company’s stock, valued at $833,400. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Charles Mcwherter acquired 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were bought at an average cost of $8.67 per share, with a total value of $43,350.00. Following the completion of the purchase, the senior vice president now owns 10,300 shares of the company’s stock, valued at $89,301. The disclosure for this purchase can be found here. Insiders sold a total of 447,257 shares of company stock valued at $3,730,862 over the last three months. Insiders own 15.10% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its holdings in CymaBay Therapeutics by 0.8% during the second quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 140 shares in the last quarter. Marshall Wace North America L.P. bought a new position in CymaBay Therapeutics during the second quarter worth about $242,000. Ardsley Advisory Partners lifted its holdings in CymaBay Therapeutics by 66.2% during the second quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after acquiring an additional 20,000 shares in the last quarter. Boothbay Fund Management LLC bought a new position in CymaBay Therapeutics during the third quarter worth about $404,000. Finally, Crestline Management LP bought a new position in CymaBay Therapeutics during the third quarter worth about $841,000. 68.77% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2017/12/02/cymabay-therapeutics-inc-expected-to-earn-fy2019-earnings-of-1-13-per-share-cbay.html.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.